We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BIMZELX (UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia)
Product name
BIMZELX
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days)
Active ingredients
bimekizumab
Registration type
EOI
Indication
Hidradenitis suppurativa (HS)
Bimzelx is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic HS therapy.